secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0000886163-24-000053
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand acquires APEIRON for $100M, adds QARZIBA royalty; raises 2024 guidance
-----------------------------------------------------------------------------

- Acquisition of APEIRON Biologics for $100M cash; up to $28M additional contingent consideration based on QARZIBA royalty thresholds by 2030/2034.
- QARZIBA is approved in EU for high-risk neuroblastoma, marketed in >35 countries by Recordati; patent protection until 2034.
- Transaction expected to close July 2024; subject to 30-day shareholder objection period and other customary conditions.
- Ligand raises 2024 revenue guidance to $140M-$157M (from $130M-$142M) and core adjusted EPS to $5.00-$5.50 (from $4.25-$4.75).
- Deal immediately accretive to EPS by ~$1.00 annualized; ~$0.50 impact in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000053/0000886163-24-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000053/lgnd-20240708.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer